EXOZYMES INC. EXOZ
are ubiquitous in modern life - they form the basis of medicines, fuels, plastics, food, and colors, among many other applications that
together contribute to our ability to live "the good life" in the modern world.
chemicals from nature via traditional extraction methods is often inefficient and often requires large amounts of biological material
to extract the necessary amounts of the desired chemical compounds. So, despite maybe being sustainable, it is not enough to supply the
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | — | — | $70.1K | — |
| R&D | $3.7M | $1.9M | $527.5K | — |
| SG&A | $6.0M | $4.1M | $1.3M | — |
| Operating income | -$9.7M | -$5.9M | -$1.8M | — |
| Pre-tax income | -$9.3M | -$5.9M | -$2.0M | — |
| Income tax | $105.2K | — | $42.3K | — |
| Net income | -$9.2M | -$5.9M | -$2.0M | — |
| EPS, basic | -1.09 | -0.89 | -0.33 | — |
| EPS, diluted | -1.09 | -0.89 | -0.33 | — |
| Shares, diluted (wtd. avg.) | $8.4M | $6.6M | $6.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $3.0M | $9.7M | $66.5K | $558.6K |
| Total current assets | $3.9M | $10.8M | $1.2M | — |
| Property, plant and equipment | $764.4K | $882.4K | $753.4K | — |
| Total assets | $6.0M | $13.0M | $3.6M | — |
| Accounts payable | $1.2M | $924.3K | $702.9K | — |
| Total current liabilities | $1.6M | $1.3M | $2.4M | — |
| Total liabilities | $2.6M | $2.6M | $3.9M | — |
| Retained earnings | -$21.1M | -$11.9M | -$6.1M | — |
| Total equity | $3.4M | $10.4M | -$384.3K | $1.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$6.5M | -$8.5M | -$1.2M | — |
| Depreciation and amortisation | $288.0K | $267.4K | $196.9K | — |
| Stock-based compensation | $2.0M | $1.1M | $281.5K | — |
| Capital expenditure | $169.9K | $396.5K | $288.7K | — |
| Investing cash flow | -$150.2K | -$359.2K | -$311.2K | — |
| Financing cash flow | -$27.7K | $18.5M | $1.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-013563.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |